Patent · US Active

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

US12109198B2 · kind B2 · utility

0Cited by

6References

5Claims

0Family size

Assignee

Fulcrum Therapeutics, Inc. · US

Inventors

Ivan Viktorovich Efremov · Sharon, US
Steven Kazmirski · Sherborn, US
Qingyi Li · Somerville, US
Lorin A. Thompson, III · Higganum, US
Owen Brendan Wallace · Zionsville, US
Shawn Johnstone · Montréal, CA
Feng Zhou · Shanghai, CN
Peter B. Rahl · Natick, US

Key dates

Filing date	Dec 20, 2022
Grant date	Oct 8, 2024
Priority date	—
Expiry date	Dec 20, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/22
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.